VHL (Von Hippel Lindau) monoclonal Antibody | MB65649

VHL (Von Hippel Lindau) monoclonal Antibody | MB65649 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human, Mouse, Rat

Application: IHC, WB

Application Range: WB 1:4000, IHC 1:150

Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008]

Storage & Stability: PBS (PH 7.3) containing 1% BSA, 50% glycerol and 0.02% sodium azide.

Specificity: von Hippel-Lindau tumor suppressor

Molecular Weight: 24 kDa (Predicted)

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: HRCA1; pVHL; RCA1; VHL1

Immunogen: Full length human recombinant protein of human VHL (NP_000542) produced in HEK293T cell.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: Purified from mouse ascites fluids or tissue culture supernatant by affinity chromatography (protein A/G)

Pathway: N/A